Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.